Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Long Term Debt of $0.00 for the year ending 2025.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -100.0% in Long Term Debt from 2024 to 2025.
- This data is from PUMA BIOTECHNOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $48.56 million | Q2 2018: $120.27 million | Q3 2018: $121.05 million | Q1 2019: $152.84 million | Q2 2019: $93.43 million | Q3 2019: $94.19 million | Q4 2019: $94.96 million | Q1 2020: $95.76 million | Q2 2020: $96.57 million | Q3 2020: $91.71 million | Q1 2021: $76.35 million | Q2 2021: $68.71 million | Q3 2021: $96.80 million | Q1 2022: $97.38 million | Q2 2022: $97.68 million | Q3 2022: $97.99 million | Q1 2023: $98.62 million | Q2 2023: $87.62 million | Q3 2023: $76.63 million | Q1 2024: $54.69 million | Q2 2024: $43.74 million | Q3 2024: $32.75 million | Q1 2025: $10.65 million | Q2 2025: $10.87 million | Q3 2025: $0.00.
- Over the full 10 years of available data (2017 to 2025), PUMA BIOTECHNOLOGY, INC.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $21.72 million | Fiscal year 2023: $65.66 million | Fiscal year 2022: $98.31 million | Fiscal year 2021: $97.09 million | Fiscal year 2020: $84.03 million | Fiscal year 2019: $94.96 million | Fiscal year 2019: $94.96 million | Fiscal year 2018: $151.89 million | Fiscal year 2017: $48.48 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: